Life Sciences Archive » September, 2017

Life Sciences - September, 2017

296 articles

• Generic Drug Lobby Can't Derail Md. Price-Gouging Law
• Dems Urge ACA Reset After HHS Boss Price Resigns
• Fed. Circ. Clears Boston Scientific In $200M Stent IP Case
• Alere Follow-On Challenge Denied Under New PTAB Guidance
• Boston Doctor Charged With Medicaid 'Double Dipping'
• VHA May Have Overpaid For Prosthetics, Watchdog Says
• Boston Boomtown: Life Sciences Driving Firm Expansions
• Celgene Hit With Expansive Antitrust Suit Over Thalomid
• PE-Backed PQ Pulls In $508M In Downsized IPO
• HHS Chief Price Resigns Amid Jet Travel Scandal
• Bayer Further Trims Covestro Stake With €1B Sale
• Ex-Katten Atty Seeks Jurors Without 'Pharma Bro' Baggage
• Health Hires: Jones Day, K&L Gates, Pierce Atwood
• FTC Loses Challenge To Popular Memory Booster Prevagen
• Judge Axes Suit Claiming GSK Landed Pair In Chinese Jail
• 4th Amendment And Shared Servers: Lessons From Shkreli
• Consider Value Vs. Budget Impact In Mass. Drug Prices
• Abbott, Alere Settle Watchdogs' Issues With $5.3B Deal
• TV Streamer Roku Leads 4 IPOs Raising $522M Combined
• Hospira Challenges Amgen's $70M Biosimilar Verdict
• Patients Who Sued Menendez Doc Get Only $1M From Insurer
• Valeant Used 'Clandestine Network' To Cook Books, Says Suit
• Attys Who Don't Correct Patent Examiners 'Sleazy': Judge
• Missing Doctor Doesn't Doom Abbott Depakote Case, For Now
• J&J Loses Bid For Rehearing Of FCA Ruling By 1st Circ.
• Becton Dickinson Offers EU Fixes For Planned $24B Bard Buy
• New Sedona Principles Stress Information Governance
• AbbVie, Amgen End Patent Fight Over Humira Biosimilar
• Alere Settles SEC Fraud Probe With $13M Payout
• Who Will Rescue The US Patent System?
• Owner Of Meningitis-Linked Pharmacy Must Forfeit $7.5M
• FDA Brass, BigLaw Attys Dish On New Promo Policies
• Czech Republic Wins Dismissal of $374M Arbitral Award
• Things To Consider Before A Patent Deal With A Tribe
• 9th Circ. Won't Revisit Key FCA Ruling Against Gilead
• Sens. Seek Investigation Of Allergan's Patent Deal With Tribe
• Woman Fights J&J's New Trial Bid After $417M Talc Verdict
• Cynosure Hit With Class Action Over 'Useless' Body System
• Medical Device Co. Blasts Geico's 'Shotgun' Kickback Suit
• Becton Planted Article To Quash Competition, Suit Says
• GSK Asks 7th Circ. For New Trial In Atty Suicide Suit
• FTC Strikes Deal Over Integra's $1B Offer For J&J Unit
• AmerisourceBergen To Pay $260M After Mislabeling Drugs
• Endo Hit With Pa. Class Action Over Opioid Marketing
• Meningitis Pharmacy Treated 'Donald Duck' And Other Fakes
• For More Value And Diversity In Outside Counsel, Go Small
• Judge Orders Beauty Co. To Stop Selling Unapproved Drugs
• The Unclear Scope Of 'All Patent Rights' In Patent Exhaustion
• St. Jude Scores Arbitration On Ex-Worker's Wage Claims
• Ex-Hunton Atty Avoids Jail For Wine-Fueled Insider Trading
• FDA Warning Wire: Inspector Blocked At Chinese Drug Co.
• Sanofi Urges Judge To Dump Antitrust Suit Over Lantus
• Sofia Vergara's Ex-Fiancé Loses Bid To End Pre-Embryo Suit
• California Proton Sale, Contractor Settlement Approved
• Deals Rumor Mill: IQiyi, Alvogen, JC Flowers
• OxyContin Maker Can't Flee City's Suit Over Opioid Crisis
• Minimize Marijuana Risks With Special Lease Clauses
• Pharmacy Seeks Plan Reinstatement In $1.5B Antitrust Suit
• Forest Labs Must Produce Mylan Docs In Antitrust Suit
• Top White Collar Crime Cases To Watch In Massachusetts
• US Asks High Court To Hold Off On 2 AIA Cases
• PTAB Invalidates Jevtana Patent Claims In Mylan Challenge
• Drugmakers Beat Health Plan's Generic Price Inflation Suit
• 16 States Won't Intervene In FCA Suit Against Compounder
• Pension Fund's Actos Suit Against Takeda Moved To Illinois
• Data Center Co. Switch Leads 2 IPOs Totaling $569M
• Amgen Hits Mylan With Patent Suit Over Neulasta Biosimilar
• FDA Cracks Down On Online Sales Of Prescription Drugs
• Ex-ArthroCare CEO Wants $750M Fraud Conviction Nixed
• Judge Rips Insider Trading Suspect's 'Arrogance'
• Manufacturers Must Focus On Securing The Internet Of Things
• How Plaintiffs And Defense Counsel Misperceive Each Other
• Mass. Marijuana Laws Could Have Far-Reaching Impact
• Amgen Gets $70M In Biosimilar Patent Suit Against Hospira
• Ex-Hunton Atty Seeks No Jail Time For Tipping Off Friend
• Drug Cos. Behind On Safety Studies, Researchers Say
• Merck's Idenix Denied Enhanced Damages On $2.5B Verdict
• 5 Firms To Guide IPOs Totaling $1.25B As Deals Gain Steam
• Taxation With Representation: Cravath, Hogan, Skadden
• CVS Customers Kiss Drug Packaging Claims Goodbye
• Restasis Patent Challenges Must Be Tossed, Tribe Tells PTAB
• Aegerion To Pay $40M To End Host Of Juxtapid Claims
• Pharma Insider-Trading Suspect Arrested Again
• Meningitis Pharmacist Shrugged Off Safety Rules, Jury Told
• J&J Unit Presses Pa. Judge To Toss $57M Pelvic Mesh Verdict
• Ky. AG Hires Motley Rice, Others In Opioid Fight
• Mass. Digital Health Developments: What To Know Now
• Herbalife Scams Consumers With 'Event System,' Suit Says
• 11th Circ. Seeks Texas Justices' Input In J&J Mesh Suit
• Momenta, Amphastar Fight Jury Decision In $1B Patent Suit
• Dow's Appeal Of $455M Award To High Court Won't Be Easy
• Doctor Tearfully Recalls Outbreak In Meningitis Murder Trial
• 1st Pa. County Sues Opioid Makers Over Addiction Epidemic
• Investors Seek Fees While Altor-NantCell Deal Suit Goes On
• Italy's €183M Pharma Antitrust Case Gets Boost From EU AG
• Breckenridge Admits Sensipar Generic Violates Amgen Patent
• FDA Warns Of Liver Damage, Deaths With Intercept Drug
• Extending CalPERS V. ANZ Securities To Exchange Act Cases
• CEO's Oversight Doesn't Merit $1M Tax Penalty, Judge Says
• Feds Fight Shkreli Bid To Release $5M In Bail Funds
• Recent Cases Provide Hope For Reverse-Payment Defendants
• What The DOJ's Elite Health Fraud Squads Are Watching
• 3rd Circ. Lets GSK Win Stand In Wellbutrin Pay-For-Delay Row
• J&J Unit Must Face Whistleblower's Retaliation Case
• Germany-Based Schenck Valued At More Than €700M In Sale
• The Role Legal Finance Can Play In Firm Year-End Collections
• Patent For Cholesterol Drug Livalo Is Valid, Judge Rules
• Calif. Jury Clears Vestagen In Med-Scrub False Ad Trial
• New Trial Granted In DePuy Hip Replacement Litigation
• New Group Aims To Protect American IP In Trade Deals
• Gore Can't Slip Invalidity Verdict In Stent Patent Row
• Xarelto Bellwether Loser Says New Study Merits Retrial
• J&J Blocking Remicade Biosimilar Sales, Pfizer Says
• 4th Bellwether Over J&J Metal Hip Implants Kicks Off
• Miami Woman Gets 4 Years For Spa Silicone Injection Scheme
• Fla. Doctor Gets 8 Years For Role In $4.8M Medicare Fraud
• OvaScience Board Seeks Derivative Case Transfer To Mass.
• Meningitis Murder Trial Dogged By Accusations Jurors Misled
• Caution In Mixing Methadone, Benzos Can Reduce Risk: FDA
• Goodwin Procter DQ Bid Pauses Teva-Impax Indemnity Suit
• FDA Cherry-Picking Record In Sensipar Case, Amgen Says
• Alibaba-Backed Best Leads 5 IPOs Raising Nearly $1B
• $146M Deal In Aggrenox Pay-For-Delay MDL Gets Initial OK
• It's On Plaintiffs To Prove No Scientific Substantiation
• 'Per-Doc' Pricing Can Improve Document Review
• Medical Scrubs Cos. Start Trial Trading False Ad, IP Claims
• InSys Says Board Acted On Compliance Issues With Narcotic
• Maine Lab Accuses Chinese University Of Selling Its Mice
• Wellstat Wins $56M In Row With Chemo Antidote Sales Partner
• Warner Chilcott Seeks Out Of Asacol Antitrust Suit
• AstraZeneca, Amneal Settle Generic Diabetes Drug Fight
• Pa. AG Touts Efforts Regarding Trump, Equifax, Opioid Makers
• Pharmacy Solely Liable For Meningitis Outbreak, Clinic Says
• FDA Warning Wire: More Belladonna Teething Pills Draw Ire
• Bayer, Janssen Win Denial Of New Xarelto Trials
• Feds Seek 51-Plus Months For Ex-Hunton Atty's Tipping
• Catalent Makes $950M Bid To Buy Cook Pharmica
• State AGs Widen Probe Into Opioid Makers, Distributors
• Pharmacist Killed Patients By Shunning Safety, Jury Told
• Troutman Sanders Nabs Mintz Levin Litigators In Calif.
• Mass. Opioid Substitution Law A Nice Idea, But Falls Short
• Ex-K&L Gates Atty Escapes Sanctions Over Withheld Evidence
• FTC Contests Impax's Defense Of Opana ER Patent Settlement
• As Medical Food Industry Grows, So May FDA Scrutiny
• A Review Of Willfulness Findings In Hatch-Waxman Actions
• Securities Cases To Watch In Massachusetts
• 3 Takeaways From Delaware's TC Heartland Venue Guidance
• AbbVie Failed To Study Risks Of AndroGel, Jury Told
• Siemens Tells 1st Circ. Brook Cleanup Verdicts Should Stand
• Hospira Tells Jury Biosimilar Was Covered By Safe Harbor
• Cancer-Focused Biotechs Launch 2 IPOs Totaling $200M
• Teva Sells Off Remaining Women's Health Assets For $1.4B
• Novo Nordisk, Benefits Co. Get Price Hike Suit Moved To NJ
• Fla. Pharmacist, Staffer Convicted For $30M Tricare Fraud
• 3rd Circ. Ends Suit Over UPenn Nuclear Researcher's Cancer
• Medical Co. Employee Defends Retaliation Claim In FCA Case
• What To Watch For In 2nd Meningitis Murder Case
• Forest Labs Seeks Quick Win In Celexa, Lexapro MDL
• Failure To Show Personal Jurisdiction In 'Show Me' State
• Large And Small Cyberrisk Solutions For Health Care Cos.
• AbbVie AndroGel Patent Suits Baseless, Pa. Judge Finds
• Medix Hits Ex-Pharma Staffing Exec With Noncompete Suit
• NY Tribe's Attorney Defends Allergan Patent Deal
• 6 Firms To Steer IPOs Worth $1.6B As E-Commerce Leads Way
• Allergan IP Deal With Tribe Could Have Big Impact On PTAB
• DOJ Director Turned Sessions Aide Tapped For Civil Division
• CEO's Unreported Bank Account Was No Accident, IRS Says
• Ill. Firm Wants Cut Of Suit It Didn't Work On, Ex-Client Says
• 2nd Circ. Axes J&J Win In Pfizer Advertising Feud
• Allergan To Pay $15M To End Asacol Antitrust Claims
• In 9th Circ., Facts Can Doom Forward-Looking Statements
• Are Opioids The New Tobacco?
• A Guide To The Executive Branch Official Nomination Process
• Fed. Circ. Affirms PTAB Nix Of MiMedx Tissue Graft Patent
• No New Trial For GSK In Suit Over Reed Smith Atty's Suicide
• Allergan Deal May Set Stage For More Tribal Patent Pacts
• Thoratec Hid Heart Device Risks, Investor Tells 9th Circ.
• Puma Investor Seeks Fees For $20M In Director-Pay Savings
• 'Rule Of 2' Need Only Be Met At Start Of Deal, GAO Says
• FDA Clears Amgen-Allergan Biosimilar Of Genentech's Avastin
• Alcon Fights Bid For Docs In Contact Lens Antitrust MDL
• Pain Clinic Can't Depose FDA In Meningitis Cases, Feds Say
• 3rd Circ. Wellbutrin Ruling May Hinder Pay-For-Delay Suits
• FDA Backs 1st Mobile App For Substance Use Disorders
• OIG's Warranty Safe Harbor Opinion And Value-Based Care
• Ransomware And Medical Devices: A Growing Risk
• Abbott Must Pay $38M Depakote Verdict, Mo. High Court Says
• Full Fed. Circ. Urged To Review Inequitable Conduct Ruling
• CBS Sheds Doc's Defamation Suit Over Pill Crisis Coverage
• California Proton Reaches Deal For Facility Transition
• PharMerica Investor Sues Over $1.4B KKR, Walgreens Buyout
• High Court Asked To Review Mass Action Challenge
• Martin Shkreli In Custody After Clinton Comments
• Dynavax Escapes Shareholder Suit Over Hepatitis Vaccine
• Small Cos. Need Relief From Audit Rules, SEC Panel Told
• 5th Circ. Affirms Toss Of FCA Suit Against AndroGel Maker
• AbbVie's Humira Patents Are Noninventive, Boehringer Says
• Ex-Hunton Atty Won't Get Do-Over Of Insider Trading Trial
• Kimberly-Clark Indemnity Suit Halted As Halyard's Proceeds
• Del. Chief Judge Sets Post-TC Heartland Venue Guidelines
• FDA Warning Wire: Strychnine In Homeopathic Drugs
• Dow Asks Justices To Weigh In On Bayer $455M Award Row
• Indicted Insys Execs Face October 2018 Trial
• Judge Dismisses Ixchel's Antitrust Claims Against Biogen
• DOJ Backs Biosimilar Makers In Info-Sharing Fight
• Calif. High Court Should Hear Antitrust Query, AG Says
• Panamanian Drug Payment Row Heads To Arbitration
• Special Master To Oversee Discovery In J&J Talc MDL
• Health Plans Want RICO Suit Against Abbott Rebooted
• Home DNA Testing Co. 23andMe Raises $250M
• What The Intel Decision Means For European Commission
• GCs Pick 5 Fave Firms For Their Product Liability Work
• PTAB Grants Celgene Rehearing In Cancer Drug Challenge
• FDA Chief Backs Streamlined Studies To Curb Drug Costs
• Drugmakers Slam Ohio AG's Suit Over Opioid Crisis
• Impax Can't Stay Teva Suit During Goodwin Procter Appeal
• Diarrhea Drug Abuse Shouldn't End OTC Sales, FDA Hears
• 1st Circ. FCA Ruling May Spawn 'Parasitic' Suits, J&J Says
• Squire Patton Boggs Adds Obama IT Chief As Adviser
• Supreme Court Applied 'Settled Principles' In BMS Ruling
• Why More Global Giants Are Renouncing Their HQs
• Where The Global 20 Are Bolstering Their Ranks
• Global Firms Snap Up India Work With Liberalization In Limbo
• Firms Stay The Course On London Growth Amid Brexit Haze
• Law360 Reveals The Global 20 Firms Of 2017
• AmerisourceBergen Eyes $260M Deal In Criminal FDA Case
• 8th Circ. Again Revives FCA Suit Over Bayer Cholesterol Drug
• UK Drugmaker Can't Dodge States' Suboxone Case Just Yet
• Shkreli Looks To Kill Conspiracy Charge Post-Trial
• Amgen Set To Face Off With Hospira In Biosimilar IP Trial
• Galena To Pay $7.5M To Settle Opioid Kickback Suit
• Allergan Transfers Restasis Patents To IPR-Immune Tribe
• Innoviva Warns Of Bad Precedent Risk In Proxy Drop Battle
• Pa. Marijuana Grower Failed To Disclose Probe, Suit Says
• 3rd Circ. Keeps Grand Jury Seal In Bone Cement Test Suit
• Buchanan Ingersoll Scores Merchant & Gould Drug Patent Pro
• Doc Says Anti-SLAPP Law Can't Sink Defamation Suit
• J&J Unit Escapes Bulk Of Surgical Stapler Liability Suit
• Taxation With Representation: Wachtell, DLA, Simpson
• J&J Mesh Cases Belong In Philly, Out-Of-State Residents Say
• Ex-Covidien Employee Can't Escape Contract Breach Suit
• FDA Slams EpiPen Maker For Not Investigating Defects
• Supplement Co. Wins Partial Dismissal Of False Ad Suit
• Health Hires: AIG, Debevoise, Hinckley, K&L, PhRMA, Stinson
• Aligning A Product's Marketing, Regulatory And IP Plans
• How Collaboration Is Changing Inside Some Law Firms
• Profs Urge 3rd Circ. To Rethink GSK Win In Wellbutrin Case
• Kite Pharma Investors Balk At $11.9B Gilead Deal
• Feds Want Shkreli's Bail Revoked Over Clinton 'Threat'
• Swiss Pharma Co. Seeks OK On Cystic Fibrosis Drug Award
• Luxembourg Decision On $383M Award An Outlier, Court Told
• No Kickback Fines For Pharmacy Discounts, HHS OIG Says
• Travel Agency Leads 4 IPO Launches Totaling $375M
• Sanofi Beats Eye Doctor's TCPA Suit Over 13-Year-Old Fax
• $4.5M Deal In False Supplement Ad Suit Gets Final Nod
• FDA Invites Public To Weigh In On Regulatory Reform
• J&J Defends Privileged Docs In Contact Lens Antitrust MDL
• J&J Slammed With $57M Verdict In Philly Mesh Case
• 4 Cases That Will Guide The Future Of TTAB Proceedings
• Dealing With Difficult Lawyers
• Theranos Gets Class Limited To Indirect Share Purchasers
• McCaskill Slams Opioid Drugmaker Over Sales Efforts
• Daiichi Wants In On RoxyBond Rival's FDA Challenge
• Praxair Prevails In Mallinckrodt's Respiratory Drug Patent Suit
• FDA Releases Guidance On Connected Medical Devices
• NY Pharmacist Pleads Guilty To Illegal Distribution Scheme
• Impax To Pay $4.8M To End 'Fax-Blasting' Suit
• CORRECTION: AbbVie Can't Argue AndroGel Suit Too Late
• Ex-Roche Worker, Insurer Settle Suit Over Malpractice Ruling
• Punitive Damages In Mass Torts: Outrageous And Reckless
• Novo Nordisk Pays $60M To End Probe Into Drug Marketing
• Judge's Meddling Undoes Bio-Med Convictions, Justices Told
• Illumina Blasts Ariosa's $100M Counterclaim In Patent Suit
• FDA Warning Wire: Unapproved Surgeries On Kids Draw Fire
• SEC Inks $6.5M Deal In Marijuana Stock Fraud Row
• IRS Can Keep Docs Out Of CEO's $1M Tax Penalty Trial
• Philly Jurors Start Work As 6th Pelvic Mesh Trial Wraps
• CTI BioPharma Settles Investor Testing Info Row For $20M
• Saul Ewing, Arnstein & Lehr Merger Yields 15-Office Firm
• Simpson Thacher Guides Teleflex's $1.1B Bid For NeoTract
• Failed Biotech's Investors Warn Of 'Chilling' Wage Suit
• Merck Asks Supreme Court To Halt Fosamax Warning MDL
• Calif. High Court Tax Decision Could Be A Pyrrhic Victory
• 5th Circ. Wants Texas Hip Implant Bellwether Axed
• Fed. Circ. Affirms CardiAQ Win In $112M Trade Secret Row
• Taxation With Representation: Skadden, Sullivan, Hogan
• Fired Pharma Exec Not Victim Of Retaliation, 3rd Circ. Says
• Nightstar Marks Latest Foreign Biotech To File US IPO
• Dr. Reddy's Cleared Of Infringing Suboxone Patents
• Get 'Ultra-High Dose' Opioids Off Market, FDA Is Urged
• CIT Raps Commerce For Agilent Duty Ruling
• HHS Seeks Another Delay Of 340B Drug Price Ceilings
• 3rd Circ. Asked To Rethink Wellbutrin Pay-For-Delay Ruling
• Shkreli Trial And Other Magic Tricks: A Chat With Ben Brafman
• LabMD Says FTC Can't Delay 1st Amendment Case Appeal
• Can You Stop Photography During An FDA Inspection?